Online inquiry

IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6864MR)

This product GTTS-WQ6864MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KLKB1 gene. The antibody can be applied in Hereditary Angioedema (HAE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000892.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3818
UniProt ID P03952
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6864MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2314MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ9232MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ3332MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ5352MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ11871MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ2679MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ13407MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ2994MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW